Overview
EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC
Status:
Unknown status
Unknown status
Trial end date:
2019-07-01
2019-07-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The aim of this study was to compare the efficacy of EGFR-TKIs(Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors) treatment plus concurrent chemotherapy versus sequential treatment with EGFR-TKIs and chemotherapy in patients with EGFR(Epidermal Growth Factor Receptor)-mutant non-small-cell lung cancer (NSCLC).Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Fujian Cancer HospitalTreatments:
Cisplatin
Erlotinib Hydrochloride
Pemetrexed
Criteria
Inclusion Criteria:- Stage Ⅳ EGFR mutation-positive NSCLC
- Initial therapy
- ECOG performance status 0-1
Exclusion Criteria:
- EGFR mutation-negative
- Previous systemic antitumour treatment